Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study
This post hoc analysis identified an association between efficacy and HRQoL based on data from CheckMate 9ER. These results highlight the necessity of balancing treatment choice, tolerability, and HRQoL to optimize treatment outcomes and support shared decision-making.
Authors
- Lysbeth L. Floden (ORCID: https://orcid.org/0000-0003-0584-6227)
- Cristiane Decat Bergerot (ORCID: https://orcid.org/0000-0003-0037-0303)
- Mickael Löthgren
- Intan Purnajo (ORCID: https://orcid.org/0000-0001-9381-5644)
- David F Cella (ORCID: https://orcid.org/0000-0002-9881-4541)
- Rachel H. Giles (ORCID: https://orcid.org/0000-0001-9133-2008)
- T. Powles
- R.J. Motzer
- Alessia Ogareva (ORCID: https://orcid.org/0000-0003-0538-8107)
- Jens Bedke (ORCID: https://orcid.org/0000-0003-2778-3108)
- T.K. Choueiri
- Michael DeRosa (ORCID: https://orcid.org/0009-0002-0638-4968)
Institutions
- Northwestern University (US)
- St Bartholomew's Hospital (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Queen Mary University of London (GB)
- Ipsen (France) (FR)
- Dutch Cancer Society (NL)
- Health Outcomes Solutions (United States) (US)
- MedSIR (Spain) (ES)
- Dana-Farber Cancer Institute (US)
- Klinikum Stuttgart (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105115
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Memorial Sloan-Kettering Cancer Center
- Ipsen Fund
- Ipsen